Germany’s Merck said on March 11 that it has signed a memorandum of understanding with Kobe-based CDMO Cyto-Facto to accelerate the development and manufacturing of cell and gene therapies.Under the deal, Merck will leverage its VirusExpress 293T lentiviral production cells,…
To read the full story
Related Article
- Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
BUSINESS
- Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
April 23, 2026
- Bayer Eyes 2026 Launch for Sevabertinib under “3-Plus-3” Strategy in Japan
April 23, 2026
- iPark, Taiwan’s ITRI Ink MOU to Boost Biotech Collaboration
April 23, 2026
- AbbVie, BioLabs Partner to Support Japan Biotech Startups
April 23, 2026
- Lenvima-Keytruda Triplets Fail in First-Line RCC Trial
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





